Tolerogenic Properties of the Fc Portion of IgG and Its Relevance to the Treatment and Management of Hemophilia

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2018 Mar 29

PMID 29588277

Citations 20

Authors

Richard S Blumberg

David Lillicrap

Affiliations

Soon will be listed here.

Abstract

Hemophilia, or inherited genetic deficiencies in coagulation factors, results in uncontrolled bleeding requiring replacement therapy with recombinant proteins given preventively or on demand. However, a major problem with these approaches is the potential for development of immune responses to the administered proteins due to the underlying genetic deficiency of the factor(s) throughout life. As such, there is great interest in developing strategies that avoid immunogenicity and induce immune tolerance. Recently, recombinant factor VIII (rFVIII) and rFIX fused to the crystallizable fragment (Fc) domain of immunoglobulin G (IgG) have been developed as therapeutic agents for hemophilia A and B, respectively. Although it is well known that the possession of an Fc domain confers IgG's longer-lasting circulating half-life, it is not generally appreciated that the Fc domain also confers immunoregulatory properties that are associated with the induction of tolerance. Here, we review some of the latest advances in our understanding of the tolerogenic abilities of IgG Fc and the impact of Fc-fusion proteins of rFVIII on the treatment of hemophilia.

Citing Articles

Natural killer cells and engagers: Powerful weapons against cancer.

Bottino C, Picant V, Vivier E, Castriconi R Immunol Rev. 2024; 328(1):412-421.

PMID: 39180430 PMC: 11659922. DOI: 10.1111/imr.13384.

Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS).

Fischer K, Lassila R, Peyvandi F, Gatt A, Gouw S, Hollingsworth R Res Pract Thromb Haemost. 2024; 8(4):102461.

PMID: 39026659 PMC: 11255940. DOI: 10.1016/j.rpth.2024.102461.

Factor IX administration in the skin primes inhibitor formation and sensitizes hemophilia B mice to systemic factor IX administration.

Sherman A, Bertolini T, Arisa S, Herzog R, Kaczmarek R Res Pract Thromb Haemost. 2024; 7(8):102248.

PMID: 38193070 PMC: 10772885. DOI: 10.1016/j.rpth.2023.102248.

Antigen-dependent modulation of immune responses to antigen-Fc fusion proteins by Fc-effector functions.

Richel E, Wagner J, Klessing S, Di Vincenzo R, Temchura V, Uberla K Front Immunol. 2023; 14:1275193.

PMID: 37868961 PMC: 10585040. DOI: 10.3389/fimmu.2023.1275193.

Sequential Use of Efgartigimod and Romiplostim Restored Platelet Response in Two Multi-Refractory Thrombocytopenic Patients, Previously Treated with Thrombopoietin Receptor Agonists.

Carpenedo M, Zappaterra A, Ferrari B, Cotilli G Mediterr J Hematol Infect Dis. 2023; 15(1):e2023021.

PMID: 36908865 PMC: 10000878. DOI: 10.4084/MJHID.2023.021.

References

Baker K, Qiao S, Kuo T, Aveson V, Platzer B, Andersen J . Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells. Proc Natl Acad Sci U S A. 2011; 108(24):9927-32. PMC: 3116387. DOI: 10.1073/pnas.1019037108. View

Shapiro A, Ragni M, Valentino L, Key N, Josephson N, Powell J . Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood. 2011; 119(3):666-72. PMC: 3265197. DOI: 10.1182/blood-2011-07-367003. View

Werwitzke S, Vollack N, von Hornung M, Kalippke K, Kutzschbach J, Trummer A . Deletion or inhibition of Fc gamma receptor 2B (CD32) prevents FVIII-specific activation of memory B cells in vitro. Thromb Haemost. 2015; 114(6):1127-35. DOI: 10.1160/TH14-06-0535. View

Ragni M, Alabek M, Malec L . Inhibitor development in two cousins receiving full-length factor VIII (FVIII) and FVIII-Fc fusion protein. Haemophilia. 2016; 22(5):e462-4. DOI: 10.1111/hae.13032. View

Astermark J, Donfield S, DiMichele D, Gringeri A, Gilbert S, Waters J . A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2006; 109(2):546-51. DOI: 10.1182/blood-2006-04-017988. View

Takai T, Ono M, Hikida M, Ohmori H, Ravetch J . Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature. 1996; 379(6563):346-9. DOI: 10.1038/379346a0. View

Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert A . Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood. 2005; 107(8):3167-72. DOI: 10.1182/blood-2005-09-3918. View

Borel Y . Isologous IgG-induced immunologic tolerance to haptens: a model of self versus non-self recognition. Transplant Rev. 1976; 31:3-22. DOI: 10.1111/j.1600-065x.1976.tb01450.x. View

Samuelsson A, Towers T, Ravetch J . Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001; 291(5503):484-6. DOI: 10.1126/science.291.5503.484. View

10.

Mahlangu J, Powell J, Ragni M, Chowdary P, Josephson N, Pabinger I . Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2013; 123(3):317-25. PMC: 3894491. DOI: 10.1182/blood-2013-10-529974. View

11.

Carcao M, Shapiro A, Staber J, Hwang N, Druzgal C, Lieuw K . Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis. Haemophilia. 2018; 24(2):245-252. DOI: 10.1111/hae.13413. View

12.

Lillicrap D, Schiviz A, Apostol C, Wojciechowski P, Horling F, Lai C . Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): product characteristics and preclinical profile. Haemophilia. 2015; 22(2):308-317. DOI: 10.1111/hae.12784. View

13.

Arnold J, Wormald M, Sim R, Rudd P, Dwek R . The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol. 2006; 25:21-50. DOI: 10.1146/annurev.immunol.25.022106.141702. View

14.

Waters B, Qadura M, Burnett E, Chegeni R, Labelle A, Thompson P . Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response. Blood. 2008; 113(1):193-203. DOI: 10.1182/blood-2008-04-151597. View

15.

Eckhardt C, Astermark J, Nagelkerke S, Geissler J, Tanck M, Peters M . The Fc gamma receptor IIa R131H polymorphism is associated with inhibitor development in severe hemophilia A. J Thromb Haemost. 2014; 12(8):1294-301. DOI: 10.1111/jth.12631. View

16.

Aubin E, Lemieux R, Bazin R . Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation. Blood. 2009; 115(9):1727-34. DOI: 10.1182/blood-2009-06-225417. View

17.

Vollack N, Friese J, Bergmann S, Tiede A, Werwitzke S . CD32 inhibition and high dose of rhFVIII suppress murine FVIII-specific recall response by distinct mechanisms in vitro. Thromb Haemost. 2017; 117(9):1679-1687. DOI: 10.1160/TH17-03-0201. View

18.

Vaughn D, Milburn C, Penny D, MARTIN W, Johnson J, Bjorkman P . Identification of critical IgG binding epitopes on the neonatal Fc receptor. J Mol Biol. 1998; 274(4):597-607. DOI: 10.1006/jmbi.1997.1388. View

19.

Whelan S, Hofbauer C, Horling F, Allacher P, Wolfsegger M, Oldenburg J . Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood. 2012; 121(6):1039-48. DOI: 10.1182/blood-2012-07-444877. View

20.

Su Y, Rossi R, De Groot A, Scott D . Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se. J Leukoc Biol. 2013; 94(2):377-83. PMC: 3714563. DOI: 10.1189/jlb.0912441. View